Sputter Deposition of Titanium on Poly(Methyl Methacrylate) Enhances Corneal Biocompatibility.

Boston Keratoprosthesis artificial cornea biocompatibility poly(methyl methacrylate) (PMMA) titanium sputtered coating

Journal

Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919

Informations de publication

Date de publication:
12 2020
Historique:
received: 09 02 2020
accepted: 15 11 2020
entrez: 14 1 2021
pubmed: 15 1 2021
medline: 15 5 2021
Statut: epublish

Résumé

To evaluate titanium (Ti) sputtering of the poly(methyl methacrylate) (PMMA) stem of the Boston Keratoprosthesis (BK) as a method to enhance interfacial adhesion between the PMMA and the recipient corneal tissue. PMMA specimens were plasma treated with Ar/O By contact angle studies, the Ti coating improved PMMA hydrophilicity to match that of medical-grade Ti (Ti-6Al-4V-ELI). Ti sputtering of contact surfaces resulted in a plate-like morphology with increased surface roughness, without impacting the transparency of the BK optical component. Scratch testing indicated that the mechanical behavior of the Ti coating was similar to that of casted Ti, and the coating was stable in pull-off adhesion testing. Sputtered Ti film was highly biocompatible based on tests of cell viability, adhesion, proliferation, differentiation, collagen deposition, and keratocan expression, the properties of which exceeded those of uncoated PMMA and did not induce increased complement activation. Titanium coating of the BK stem generated a mechanically and biologically favorable interface, which may help to enhance corneal stromal adhesion and biocompatibility. Improving the biocompatibility of the BK PMMA stem may improve long-term outcomes of implantation.

Identifiants

pubmed: 33442495
doi: 10.1167/tvst.9.13.41
pii: TVST-20-2326
pmc: PMC7774111
doi:

Substances chimiques

Polymethyl Methacrylate 9011-14-7
Titanium D1JT611TNE

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

41

Subventions

Organisme : NEI NIH HHS
ID : K99 EY030553
Pays : United States

Informations de copyright

Copyright 2020 The Authors.

Déclaration de conflit d'intérêts

Disclosure: S. Sharifi, None; M.M. Islam, None; H. Sharifi, None; R. Islam, None; P.H. Nilsson, None; C.H. Dohlman, None; T.E. Mollnes, None; E.I. Paschalis, None; J. Chodosh, None

Références

Biomaterials. 2005 Jun;26(16):3113-21
pubmed: 15603806
Can J Ophthalmol. 2018 Jun;53(3):284-290
pubmed: 29784167
Nanomaterials (Basel). 2019 Apr 09;9(4):
pubmed: 30970600
Cornea. 2019 Apr;38(4):492-497
pubmed: 30681517
ACS Appl Mater Interfaces. 2016 Dec 28;8(51):35565-35577
pubmed: 27966877
Am J Ophthalmol. 2016 Feb;162:89-98.e1
pubmed: 26550696
J Proteome Res. 2012 Aug 3;11(8):4231-9
pubmed: 22698189
Mater Sci Eng C Mater Biol Appl. 2017 Sep 1;78:230-238
pubmed: 28575979
Saudi J Ophthalmol. 2015 Jul-Sep;29(3):212-21
pubmed: 26155082
Am J Ophthalmol. 2008 Mar;145(3):438-44
pubmed: 18207122
Mol Immunol. 2013 Dec 15;56(3):232-9
pubmed: 23787367
Cornea. 2017 Nov;36 Suppl 1:S15-S25
pubmed: 28968294
Transl Vis Sci Technol. 2016 Apr 28;5(2):17
pubmed: 27152247
Invest Ophthalmol Vis Sci. 2013 Jun 04;54(6):3863-73
pubmed: 23661373
Invest Ophthalmol Vis Sci. 2011 Oct 03;52(11):7799-806
pubmed: 21873663
Cornea. 2012 Dec;31(12):1432-5
pubmed: 22236785
Invest Ophthalmol Vis Sci. 2011 Jan 05;52(1):215-22
pubmed: 20739475
Ophthalmology. 2012 Aug;119(8):1530-8
pubmed: 22512986
J Biol Chem. 2005 Jul 22;280(29):27085-92
pubmed: 15908433
Scand J Immunol. 1985 Aug;22(2):197-202
pubmed: 2412280
J Biomater Appl. 2011 Sep;26(3):327-47
pubmed: 20566655
Ophthalmology. 2009 Apr;116(4):640-51
pubmed: 19243830
Ophthalmology. 2013 Jun;120(6):1195-200
pubmed: 23499061
Cell Cycle. 2016;15(2):196-212
pubmed: 26825227
Can J Ophthalmol. 2008 Apr;43(2):165-9
pubmed: 18347618
Arch Ophthalmol. 1981 Aug;99(8):1430-3
pubmed: 7020664
Vox Sang. 1998;74 Suppl 2:303-7
pubmed: 9704460
Invest Ophthalmol Vis Sci. 2003 Dec;44(12):5136-41
pubmed: 14638709
Invest Ophthalmol Vis Sci. 2008 Jul;49(7):2936-45
pubmed: 18579759
Biomaterials. 2011 Jun;32(17):4076-84
pubmed: 21427010
Biomaterials. 1993 Feb;14(3):189-92
pubmed: 8476991
Invest Ophthalmol Vis Sci. 2016 Apr 1;57(4):1927-38
pubmed: 27092719
Ocul Surf. 2018 Jul;16(3):322-330
pubmed: 29627599
Biomaterials. 2013 Dec;34(37):9365-72
pubmed: 24041426
J Invest Dermatol. 2007 Mar;127(3):526-37
pubmed: 17299435
Cornea. 2009 Aug;28(7):808-11
pubmed: 19574903
ACS Appl Mater Interfaces. 2015 Oct 7;7(39):21690-702
pubmed: 26389670
Nat Rev Mol Cell Biol. 2002 May;3(5):349-63
pubmed: 11988769
MethodsX. 2014 Nov 25;2:8-13
pubmed: 26150966
Invest Ophthalmol Vis Sci. 2011 Sep 22;52(10):7392-9
pubmed: 21849419
Proc Natl Acad Sci U S A. 1978 Feb;75(2):871-5
pubmed: 204938
Xenotransplantation. 2010 Mar-Apr;17(2):140-6
pubmed: 20522246
J Biomed Mater Res. 1998 Sep 5;41(3):422-30
pubmed: 9659612
Sci Rep. 2019 Feb 12;9(1):1876
pubmed: 30755666
Exp Eye Res. 2006 Jul;83(1):3-15
pubmed: 16580666
Dev Biol. 2010 May 1;341(1):126-40
pubmed: 19854168
Eur J Microbiol Immunol (Bp). 2012 Jun;2(2):103-11
pubmed: 24672678
Mater Sci Eng R Rep. 2017 Sep;119:1-35
pubmed: 29200661

Auteurs

Sina Sharifi (S)

Disruptive Technology Laboratory and Schepens Eye Research Institute, Massachusetts Eye and Ear; Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.

Mohammad Mirazul Islam (MM)

Disruptive Technology Laboratory and Schepens Eye Research Institute, Massachusetts Eye and Ear; Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.

Hannah Sharifi (H)

Disruptive Technology Laboratory and Schepens Eye Research Institute, Massachusetts Eye and Ear; Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.

Rakibul Islam (R)

Department of Immunology, Oslo University Hospital, Rikshospitalet, University of Oslo, Oslo, Norway.

Per H Nilsson (PH)

Department of Immunology, Oslo University Hospital, Rikshospitalet, University of Oslo, Oslo, Norway.
Linnaeus Center for Biomaterials Chemistry, Linnaeus University, Kalmar, Sweden.

Claes H Dohlman (CH)

Disruptive Technology Laboratory and Schepens Eye Research Institute, Massachusetts Eye and Ear; Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.

Tom Eirik Mollnes (TE)

Department of Immunology, Oslo University Hospital, Rikshospitalet, University of Oslo, Oslo, Norway.
Research Laboratory, Nordland Hospital, Bodø, Norway; Faculty of Health Sciences, K.G. Jebsen TREC, University of Tromsø, Tromsø, Norway.
Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway.

Eleftherios I Paschalis (EI)

Disruptive Technology Laboratory and Schepens Eye Research Institute, Massachusetts Eye and Ear; Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.

James Chodosh (J)

Disruptive Technology Laboratory and Schepens Eye Research Institute, Massachusetts Eye and Ear; Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH